

Susan E Mathers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1650725/publications.pdf>

Version: 2024-02-01

19
papers

671
citations

840776

11
h-index

940533

16
g-index

25
all docs

25
docs citations

25
times ranked

884
citing authors

#	ARTICLE	IF	CITATIONS
1	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. <i>Nature Genetics</i> , 2021, 53, 1636-1648.	21.4	223
2	Identifying who will benefit from non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in a clinical cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 280-286.	1.9	100
3	Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. <i>BMJ Open</i> , 2016, 6, e012054.	1.9	48
4	Clinical phenotypes and natural progression for motor neuron disease: Analysis from an Australian database. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2009, 10, 79-84.	2.1	47
5	Multidisciplinary care for adults with amyotrophic lateral sclerosis or motor neuron disease. <i>The Cochrane Library</i> , 2009, , CD007425.	2.8	45
6	Genome-wide Meta-analysis Finds the ACSL5-ZDHHC6 Locus Is Associated with ALS and Links Weight Loss to the Disease Genetics. <i>Cell Reports</i> , 2020, 33, 108323.	6.4	41
7	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. <i>Science Translational Medicine</i> , 2022, 14, eabj0264.	12.4	38
8	Motor neurone disease: progress and challenges. <i>Medical Journal of Australia</i> , 2017, 206, 357-362.	1.7	28
9	Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study). <i>Medicine (United States)</i> , 2020, 99, e18904.	1.0	23
10	Serial assessment of iron in the motor cortex in limb-onset amyotrophic lateral sclerosis using quantitative susceptibility mapping. <i>Quantitative Imaging in Medicine and Surgery</i> , 2020, 10, 1465-1476.	2.0	17
11	Factors to consider for motor neurone disease carer intervention research: A narrative literature review. <i>Palliative and Supportive Care</i> , 2017, 15, 600-608.	1.0	13
12	Functional characterisation of the amyotrophic lateral sclerosis risk locus GPX3/TNIP1. <i>Genome Medicine</i> , 2022, 14, 7.	8.2	12
13	Home or Residential Care? The Role of Behavioral and Psychosocial Factors in Determining Discharge Outcomes for Inpatients with Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2012, 1, 187-193.	1.9	9
14	A self-care, problem-solving and mindfulness intervention for informal caregivers of people with motor neurone disease: A pilot study. <i>Palliative Medicine</i> , 2018, 32, 726-732.	3.1	7
15	MiNDAUS partnership: a roadmap for the cure and management of motor Neurone disease. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 321-328.	1.7	4
16	Public Policy in MND Care: The Australian Perspective. , 2021, , 29-49.		4
17	Faecal incontinence. <i>International Disability Studies</i> , 1988, 10, 164-168.	0.4	0
18	Evaluating the Utility of a Structured Clinical Protocol for Reducing the Impact of Behavioural and Psychological Symptoms of Dementia in Progressive Neurological Diseases: A Pilot Study. <i>Behavioural Neurology</i> , 2018, 2018, 1-9.	2.1	0

#	ARTICLE	IF	CITATIONS
19	End of Life Care in Progressive Neurological Disease: Australia. , 2013, , 205-212.		0